Galician Biotech Company SunRock Biopharma Sells its Innovation to Debiopharm

The Galician biotech SunRock Biopharma has just reached an agreement with Debiopharm. The company from A Coruña is focused on the research of a very specific technology since it specializes in the development of therapeutic antibodies aimed at highly invasive tumors with an urgent clinical need.

SunRock Biopharma has managed to develop a unique portfolio of therapeutic antibodies and bispecific antibodies against targets that are the focus of the fight against cancer, such as the CCR9 or HER3 receptors, using different mechanisms of action than the therapies that exist on the market.

The biopharmaceutical company Debiopharm is working precisely on the development of the future standard of treatment to cure cancer and infectious diseases, which is why it has become interested in antibodies directed against highly invasive tumors with a high clinical need that the Galician biotech is investigating.

Read more about Sunrock Biopharma and find other important business news from around the world with the Born2Invest mobile app.

Sunrock Biopharma in the fight against cancer

The agreement between the two companies allows Debiopharm to access licensing options to continue the development of SunRock Biopharma’s antibodies, integrating Debiopharm’s innovative conjugation technologies, called Multilink and AbYlink, with the aim of creating new antibodies conjugated to drugs (Antibody Drug Conjugates, ADC).

Thanks to this alliance, it will be possible to develop novel ADCs directed against specific tumor antigens for the treatment of oncological diseases with unmet clinical needs, including those types of tumors that express the HER2 and HER3 oncogenes.

This is one of the most novel and promising treatments in the fight against cancer, due to the ability of ADCs to selectively attack and destroy cancer cells while minimizing damage to healthy tissues.

This therapy combines the precision of monoclonal antibodies—identical antibodies produced in the laboratory by a single type of cell of the immune system, that is, from the same stem cell—with the cytotoxic effects of small molecule drugs, offering a powerful synergy.

The specificity of antibodies allows ADCs to recognize and bind to tumor-specific antigens on the surface of cancer cells, ensuring that the toxic cytotoxic molecule directly reaches the desired target within the cell.

This approach to treatment not only improves therapeutic efficacy but also reduces systemic toxicity and side effects commonly associated with traditional cancer treatments.

“We are truly excited about the powerful synergy of SunRock’s monoclonal antibodies and bispecific antibodies with Debiopharm’s ADC platform and its clinical development capabilities,” said Laureano Simón, CEO of SunRock Biopharma.

Other success stories in Galicia

The Galician community has become a hub of innovation in the biotech sector.

In fact, 63 biotech companies are located in Galicia , which represents 7% of the total companies in this sector in our country, after Catalonia (24.5%), Madrid (16.9%), Andalusia (13 .6%), the Basque Country (9.7%) and the Valencian Community (8.9%), according to data from the latest report from the Spanish Association of Biocompanies (AseBio).

Furthermore, the Galician biotech sector is fifth in terms of its turnover over the total market (3.5%), only behind Catalonia (45.9%), Madrid (33.2%), Andalusia (5% ) and Aragon (3.7%), and ahead of the Valencian Community (2.7%) and the Basque Country (1.42%).

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Emprendedores. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.